miDiagnostics Joins NVIDIA Inception Program

Leuven, Belgium  I   July 23, 2019


miDiagnostics today announced it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data sciences.

miDiagnostics is developing a new class of near-patient diagnostic platform based on silicon chips that are embedded in credit card-sized test cards. These silicon chips, called nanoFluidic Processors, can be functionalized to allow for the measurement of virtually any type of biomarker: cells, proteins, nucleic acids and small molecules. The test cards are read by a compact reader for rapid data collection and analysis, outside a laboratory environment, by means of advanced machine learning algorithms.

“We are very excited to be included in this inception program. By tapping into the vast algorithmic know-how and exceptional computational optimization expertise offered by the NVIDIA ecosystem and Inception program, we can further accelerate our software R&D programs. In addition, it will allow us to increase the maturity of our current algorithmic solutions to a commercial-grade level,”

Jan Fransens, Director of Algorithms and Software


NVIDIA’s Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.




miDiagnostics is using silicon chip technology which will bring miniaturized, rapid, easy-to-use, lab-quality tests with built-in connectivity direct to the patient and clinician.
Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure virtually any biomarker from an easily accessed sample such as drops of fingerprick blood. The Company is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases.
Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital technologies, imec, and a research collaboration with Johns Hopkins University, the leading US research and medical centre, miDiagnostics’ goal is to enable fast, comprehensive and cost-effective health analysis, regardless of location.  Based in Leuven, Belgium, miDiagnostics is a privately held company created in 2015.
Learn More

Share This

Copy Link to Clipboard